stockrow
Friday 6 November 2026
Export VXRT’s income statement to Excel — free account
VAXART, INC.
VXRT Healthcare Biotechnology
VAXART, INC.’s revenue for fiscal 2025 (year ended December 2025) was $237.3 million, up 726.7% from fiscal 2024.
- Revenue
- −85.3%
- EPS
- −75.0%
- Free cash flow
- −57.2%
Quarter to September 2026, against a year earlier
0.37
0.03
−7.50%
Follow VXRT
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
7 | 6 | 6 | 6 |
+8 more TTM periods Free account |
| 62.42% | 66.97% | 53.10% | 22.26% | ||
| 16.26% | 23.44% | 21.91% | 9.26% | ||
ROIC |
2,542.26% | 134.59% | 72.11% | 47.09% | |
Return on Tangible Assets |
50.50% | 78.61% | 62.15% | 29.79% | |
Average Days of Receivables |
61.41 | 70.57 | 82.21 | 78.99 | |
Free Cash Flow per Share |
0.13 | 0.14 | 0.06 | 0.03 | |
Free Cash Flow |
31.98 | 33.40 | 14.80 | 7.57 | |
Capital Expenditures |
(0.84) | (0.58) | (0.45) | (0.14) | |
| Other line items | |||||
Cash ROIC |
24.25% | 22.82% | 9.54% | 5.00% | |
Accounts Receivable Turnover |
3.11 | 5.52 | 6.94 | 7.49 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.02) | (0.01) | (0.01) | (0.03) | |
Research and Development Expense of Revenue |
72.35% | 75.81% | 78.34% | 84.96% | |
Selling, General and Administrative Expense of Revenue |
11.02% | 7.89% | 6.72% | 7.42% | |
Share Based Compensation of Revenue |
3.13% | 2.68% | 2.87% | 3.50% | |
Interest Coverage |
— | 18.03 | 16.38 | 6.40 | |
Operating CF/Net income |
1.13 | 0.88 | 0.41 | 0.47 | |
Depreciation/Fixed assets |
0.00 | 1.04 | 1.50 | 1.53 | |
Capex/Depreciation |
0.00 | (0.10) | (0.06) | (0.02) | |
Revenue per Share |
0.75 | 1.00 | 1.06 | 1.03 | |
Operating CF per Share |
0.14 | 0.14 | 0.06 | 0.03 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026